Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIP-01
- Development stage
- Unknown
- Lead developer
- CV Technologies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LIP-01 is a **small molecule drug** being developed primarily for the treatment of **hypercholesterolemia**. It was investigated in a Phase 1 clinical trial designed to evaluate its safety, tolerability, and dosing in individuals with elevated cholesterol[1][6]. There is limited available public information on its precise mechanism of action, molecular targets, or other therapeutic indications. The drug was originated by Afexa Life Sciences, Inc., and its clinical development status is currently Phase 1. Data do not support classification as a dietary supplement or non-pharmaceutical agent[6][1].
- Brand names
- LIP-01LIP01LIP 01
- Other names
- Dilexaponan
Beyond the preview
Go deeper on LIP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIP-01.